




Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct
inhibitor of protein phosphatase 2A (PP2A) activity and
overexpressed in acute myeloid leukaemia
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To the Editor:
The family of serine/threonine phosphatases (PP2A) fre-
quently shows reduced activity in myeloid leukaemias
[1, 2]. This is particularly the case in acute myeloid leu-
kaemias (AML) driven by overexpression or constitutively
active c-KIT and FLT3, where PP2A inhibition is required
for cell transformation which enhances the activation of
oncogenic signalling pathways and promotes anti-apoptotic
processes [2–4]. In myeloid malignancies, pharmacological
activation of PP2A using Forskolin, the immunosuppressant
FTY720 (reviewed in [2]) and the non-immunosuppressive
chiral-deoxy analogue of FTY720, AAL(S) has a potential
therapeutic benefit [4, 5]. FTY720 is the most well-
characterised PP2A-activating compound and phosphory-
lated by SPHK2 in vivo [6]. FTY720-P acts as a high-
affinity agonist for four of the five G protein-coupled
sphingosine-1-phosphate receptors (S1PR), causing recep-
tor internalisation and increased activity of the JAK2–
PI3Kγ–PKC signalling axis, a common molecular driver of
myeloproliferative neoplasms [7]. Phosphorylation has
been shown to be dispensable for the anti-leukaemic
activity of FTY720 [4, 5]. Furthermore, dose-limiting
toxicities are associated with S1PR activation at the anti-
neoplastic dose (FTY720-P) [8]. Non-phosphorylated
FTY720 binds to the nuclear proto-oncogene SET in leu-
kaemia cells, driving PP2A activity and apoptosis [9].
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Non-phosphorylatable analogues of FTY720 also inhibit
proliferation and induce apoptosis in several cancer cell
lines including AML cell lines and patient samples through
the activation of PP2A [5]. However, the molecular targets
of these novel chemicals are unknown.
To determine protein targets of AAL(S) and FTY720 in
myeloid progenitor cells driven by constitutively active c-
KIT, isogenic growth factor-dependent FDC.P1 myeloid
progenitor cell lines expressing either an empty vector (FD-
EV) or factor independent c-KIT/D816V [3] were subjected
to a chemical proteomics screen. Proteins competitively
eluted from AAL(S)- or O-FTY720-agarose affinity beads
(Supplementary Fig. S1A) using native drug (250 nM AAL
(S) or FTY720) in non-reduced lysates were excised and
subjected to LC-MS/MS; identifying the Shwachman–
Bodian–Diamond syndrome (SBDS) protein as a direct
target (Fig. 1a, b). SBDS loss-of-function (LOF) mutations
cause the Shwachman–Diamond syndrome (SDS),
which leads to bone marrow failure, with SDS patients
predisposed to leukaemic transformation, particularly AML
[10]. The inhibition of PP2A in myeloid leukaemias is
associated with the overexpression of the PP2A inhibitory
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Protein Gene kDa Mas. Cov.
PP2A-A Pr65 65 989 37%
B55α Ppp2r2a 52 75 5%
PP2Ac Ppp2ca 36 613 35%
SET Set 33 136 8%
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Fig. 1 SBDS is target of PP2A-activating drugs and a PP2A-
interacting protein. a Silver-stained gel of proteins pulled down by
AAL(S)-drug affinity beads eluted using excess native drug (250 nM
AAL(S)) in factor-dependent (GM-CSF) control myeloid progenitor
cells (FD-EV) and c-KIT/D816V cells. The red arrowhead indicates the
band excised and subjected to LC-MS/MS. Western blot analysis
confirmed SBDS as a target of AAL(S) using both hydrophilic- (top)
and hydrophobic- (bottom) AAL(S)-drug affinity beads. b Western blot
confirmation of SBDS as a target of O-FTY720-beads (hydrophobic-
beads) eluted using native drug (250 nM FTY720 or 250 nM AAL(S))
and further eluted using denaturing conditions (SDS). PP2Ac and SET
were also eluted using reducing conditions. c Proteins identified by LC-
MS/MS enriched following SBDS co-immunoprecipitation (CoIP)
from c-KIT/D816V cells. d Western blot confirmation of SBDS CoIP
LC-MS/MS results. e Reciprocal CoIP using PP2Ac as bait confirming
SBDS–PP2A interactions. f Protein–protein docking of SBDS (red)
with PP2A subunits Aα (green), B55α (purple) and Cα (blue) predicts
SBDS NTD to directly bind to PP2Ac and PP2A–B55α. g Docking
with SBDS indicates that AAL(S) (orange) and FTY720 (green) form
hydrogen bonds (S61, Q94), a salt bridge (E28) and hydrophobic
interactions (L12, V15) with the NTD of SBDS, in the region sur-
rounded by predicted binding sites with PP2Ac (blue) and B55α
(purple). h Site directed mutagenesis induced alanine substitutions;
SBDS mutants, L12A/V15A, E28A, S61A and Q94A were over-
expressed, purified and used in AAL(S)-drug bead affinity chromato-
graphy. SDS-PAGE gel shifting occurred in the E28A mutant to
increase gel migration by the binding of additional SDS molecules,
without altering the secondary structure. i Quantitative assessment of
AAL(S) and FTY720 affinity for wild-type (WT) and alanine mutant
SBDS using recombinant protein, and in silico alanine mutant PDB
SBDS structures.
3394 M. D. Dun et al.
protein SET [9]; however, using our chemical proteomics
approach the catalytic subunit of PP2A, PP2Ac (PPP2CA)
and SET were only eluted from AAL(S)- or FTY720-beads
under denaturing conditions and not following competitive
drug elution; albeit considerably less SET was eluted from
AAL(S)-beads than from O-FTY720-beads (Fig. 1b).
Likewise, SBDS further eluted from the beads using
denaturing conditions, suggesting that both monomeric
SBDS and PP2Ac macromolecular complexes comprised of
SBDS and SET bind to AAL(S) and FTY720.
To independently identify SBDS interacting proteins,
SBDS immunoprecipitates from c-KIT/D816V cells were
subjected to LC-MS/MS (Supplementary Fig. S1B). Pep-
tides were mapped with high confidence to SBDS, PP2Ac,
PP2A structural subunit (PP2A-A), PP2A regulatory sub-
unit B55α (B55α), nucleophosmin (NPM1) and SET
(Fig. 1c and Supplementary Fig. S1B). No other PP2A
regulatory subunits were identified. These novel and spe-
cific interactions were then validated in c-KIT/D816V cells
using reciprocal co-immunoprecipitation with both SBDS
and PP2Ac antibodies (Fig. 1d, e and Supplementary
Fig. S1B).
Potential direct binding of SBDS to PP2A and PP2A-
activating drugs AAL(S) and FTY720 was further investi-
gated in silico using all available nuclear magnetic resonance
structures of SBDS. This analysis identified an amphipathic
binding pocket within the N-terminal domain of SBDS that
likely interacts with PP2A–B55α complexes (Fig. 1f). This
region corresponded well with binding hot spots identified
using the solvent mapping platform FTMap [11] (Supple-
mentary Fig. S1C). We next docked AAL(S) and FTY720
into SBDS, which predicted them to bind Serine 61 (S61)
and glutamine (Q94) to form hydrogen bonds, while glu-
tamic acid 28 (E28) formed a salt bridge with the amino
alcohol region of AAL(S) and FTY720. Leucine 12 (L12)
and valine 15 (V15) were predicted to associate within a
small hydrophobic pocket localised in the N-terminal FYSH
domain (Fungal, Yhr087wp and Shwachman) (Fig. 1g).
Using site directed mutagenesis, amino acids predicted to
bind with AAL(S) and FTY720 were modified to alanine
and the affinity of AAL(S) to bind SBDS determined bio-
chemically (Supplementary Table S1). Mutagenesis of E28
to alanine (E28A) significantly reduced affinity (−61%, p=
0.011) (Fig. 1h, i). Increased affinity for the control beads
lacking the amino alcohol moieties of AAL(S) was seen in
L12A/V15A and S61A mutants, highlighting a role for the
hydrophobic tail of AAL(S) and FTY720 in SBDS binding
(Fig. 1h—Cont.-beads). It is interesting to note that the
hydrophobic FYSH region of SBDS is predicted to be the
site of interaction with PP2Ac and PP2A–B55α subunits
(Fig. 1f, g). This interaction may modulate the activity of
PP2Ac by blocking substrate phosphopeptides from binding
and hence prevent their dephosphorylation. Little to no
affinity for either the AAL(S) or control beads was seen
using a control protein, recombinant pro-NGF, which has a
similar molecular weight as SBDS (27 kDA) and not pre-
dicted to bind AAL(S) or FTY720 (Supplementary
Fig. S1D). In silico analysis of the binding energies between
AAL(S) and FTY720 and the wild-type SBDS (Protein Data
Bank (PDB) archive: accession codes SBDS-2L9N [12])
and alanine mutant SBDS proteins also showed that the
affinity was greatly reduced for the E28A mutant for both
AAL(S) and FTY720 (−60.1% and −84%, respectively)
(Fig. 1i). This is due to the removal of the salt bridge
interaction between the primary amine head group (on both
AAL(S) and FTY720) in the E28A mutant. These data
further highlight that AAL(S) and FTY720 can interact with
SBDS bound and unbound to PP2Ac/PP2A-A/B55α
complexes.
We have previously shown that PP2A activity is reduced
in myeloid cells and patients blasts harbouring con-
stitutively active c-KIT/D816V and FLT3/ITD compared
with GM-CSF-dependent FD-EV cells and activity is
increased using FTY720 and AAL(S) [3–5]. Here, we
confirmed this and showed that shRNA-mediated knock-
down of SBDS (shSBDS) increased PP2A activity (Fig. 2a),
through reduced affinity and co-localisation with PP2A
(Supplementary Figs. S2A and S2B, respectively). Notably,
the addition of recombinant SBDS to PP2A immunopreci-
pitates reduced PP2A activity in both the c-KIT/D816V and
FD-EV cells (Fig. 2a).
Sbds LOF mutations in cells of the myeloid lineage
drives apoptosis in myelocytes and their respective down-
stream progeny, while loss of Sbds is well tolerated by
cycling haematopoietic progenitor cells [10]. Transient
knockdown of SBDS in constitutively active c-KIT/D816V
myeloid cells increased cleaved caspase 3 and apoptosis
compared with their scrambled shRNA controls (SCRM)
(Fig. 2b, c and Supplementary Fig. S2C), while it decreased
cell proliferation (Fig. 2d). However, factor-dependent FD-
EV myeloid cells showed no reduction in viability (Fig. 2d)
or proliferation compared with their controls. This was
further reflected by a reduction in the percentage of cells
expressing the SBDS knockdown over time only in the c-
KIT/D816V cells (Fig. 2e). Taken together, these data
showed that the inhibition of SBDS increased PP2A activ-
ity, inhibited proliferation and induced cell death in myeloid
cells harbouring constitutively active c-KIT/D816V. Whe-
ther LOF of SBDS in myleocytes of SDS patients drives
overactivation of PP2A and promotes apoptotic process
remains to be determined, but if true would suggest that
therapies that reduce PP2A activity may help to reduce
dysfunctional myeloblast differentiation commonly seen in
SDS patients.
To determine the clinical relevance of SBDS expression
in AML, we assessed SBDS mRNA expression in normal
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bone marrow CD34+ cells from healthy subjects (n= 12),
and compared expression with AML patient blasts at
diagnosis (n= 428) and AML patient blasts at relapse (n=
23) using the publicly available Beat AML data viewer
(www.vizome.org) [13, 14]. These analyses showed that at
diagnosis, AML patients expressed significantly more SBDS
mRNA than healthy controls (Mann–Whitney test p=
0.0002), while patients that relapsed after chemotherapy
expressed significantly more SBDS mRNA than both heal-
thy controls and patients at diagnosis (Kruskal–Wallis test
p= 0.0004) (Fig. 2f), highlighting SBDS as a novel drug
target. To determine the potential of SBDS protein as a drug
target we assessed SBDS protein expression via immuno-
histochemistry using bone marrow trephine biopsies from a
core binding factor-AML patient (Inv(16)(p13.1;q22) also
harbouring a c-KIT mutation (M541L). This analysis
showed high SBDS expression at diagnosis, whereas no
SBDS protein expression was seen in their matched
remission sample following standard of care treatment, or in

















































Fig. 2 SBDS inhibits PP2A activity and is essential for the survival
of c-KIT/D816V mutant cells. a PP2A activity was assessed fol-
lowing molecular inhibition of SBDS using SBDS shRNA, or treat-
ment of FD-EV and c-KIT/D816V cells for 12 h with 250 nM AAL
(S). FD-EV and c-KIT/D816V cells were transiently transfected with
YFP-tagged scrambled shRNA controls or two different YFP-tagged
SBDS shRNA constructs for 24 h, and then sorted for populations of
cells expressing high YFP. b Cells were then stained 24 h post sort
with Annexin V, quantitation of dead cells post sort was measured by
Annexin V+ and 7AAD+ cells as a percent of scrambled controls.
c Western blot for caspase 3 following transient SBDS knockdown.
d c-KIT/D816V cells harbouring the knockdown of SBDS (shSBDS-
A, orange; shSBDS-B, red) showed significantly reduced proliferation
compared with scrambled shRNA controls (FD-EV, grey; c-KIT/
D816V, green) and FD-EV SBDS knockdown (shSBDS, black)
determined by the Trypan blue exclusion assay, and e reduced YFP+
cells as determined via flow cytometry (**p < 0.01, Two-way
ANOVA). f SBDS RNA-sequencing data from primary AML blast
samples from 428 AML patients at diagnosis, 23 patients following
AML relapse, and SBDS expression in normal bone marrow CD34+
cells from 12 healthy controls. Data extracted from the Beat AML®
cohort and were analysed using www.vizome.org. g Trephine biopsies
from an AML patient harbouring a c-KIT mutation at diagnosis and
following successful treatment with standard of care chemotherapies,
and a trephine biopsy from a healthy control immunostained for
SBDS.
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Although the mechanism underpinning the increased SBDS
mRNA and protein expression in AML blasts both at
diagnosis and relapse are not known, these data go some
way to describe why AML patients myeloblasts show
reduced PP2A activity compared with normal myeloblasts
[1, 4].
Our study provides a novel mechanism of PP2A inhibi-
tion in myeloid progenitor cells harbouring mutant c-KIT.
SBDS is a target of FTY720 and AAL(S), with SBDS
expression essential for the factor independent survival of
these mutant c-KIT cells. Significantly higher SBDS
expression is seen in AML patients at diagnosis, exacerbated
at relapse, highlighting the need for future investigations
focused on the role SBDS plays in leukemogenesis and
future drug targeting, particularly in the relapse setting [15].
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